Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype

@inproceedings{Carbone2013AntiVEGFTP,
  title={Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype},
  author={Carmine Carbone and Geny Piro and Anna Tamburrino and Maria Mihaela Mina and Silvia Zanini and Giampaolo Tortora and Davide Melisi},
  year={2013}
}
Context The resistance of tumors to antiangiogenic therapies is becoming increasingly relevant. There are currently no validated predictive biomarkers for selecting which cancer patients will benefit from antiangiogenic therapy. Also lacking are resistance biomarkers that can identify which escape pathways should be targeted after tumors develop resistance to VEGF treatment. Recent studies showed that anti-VEGF treatment can make tumor cells more aggressive and metastatic. However, the… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 41 CITATIONS

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 9 EXCERPTS
CITES BACKGROUND

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer

  • International journal of molecular sciences
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance

  • Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND